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Background: Non-surgical periodontal treatment (NSPT) is widely employed for the treatment of periodontal disease and yields significant clinical improvements. Gingival crevicular fluid (GCF) can be used to profile health and disease and recent technological advances, such as multiplex bead immunoassays, are promising in identifying a wider array of GCF factors with the ultimate aim to predict the treatment response. 
Objective: The aim of this systematic review was to compare the expression of GCF markers using multiplex bead immunoassays before treatment and during early, average or late healing period, following non-surgical periodontal treatment (NSPT). 
Methods: An electronic literature search was conducted by two independent examiners (VK and NC) in MEDLINE, EMBASE, OpenGrey, LILACS and Cochrane Library up to January 2020. The PICO question formulated was: “In patients with periodontal disease, does the expression of gingival crevicular fluid (GCF) markers detected using multiplex bead immunoassay differ at baseline compared with early (≤30 days), average (6-8 weeks) or late (≥3 months) healing after intervention?” 
Results: A total of 366 publications were obtained and reviewed for eligibility for inclusion. Of these, 12 publications fulfilled the inclusion criteria and were included in the present review. Data for a total of 31 different GCF markers was extracted and summarized for early, average or late healing after NSPT. Early healing following NSPT (≤ 30 days), indicated an increase in IL-1β, TNFα and IL-10. At the average healing period (6-8 weeks), IL-1β, IL-1α, IL-6, TNF-α, IFN-γ, GM-CSF, MCP-1, MIP-1α were all reduced, compared to their respective baseline values. Three months after NSPT IL-1β, IL-4, IL-6, IL-10, TNF-α and IFN-γ were detected at reduced levels, compared to pre-treatment levels, Overall, the changes following treatment indicated a reduction of inflammation present at baseline.
Conclusion: Following non-surgical periodontal treatment, an upregulation of inflammation markers is noted early post-operatively and a subsequent reduction of their levels three months following treatment. The investigation of levels of GCF markers associated with inflammation and regeneration, especially using multiplex bead immunoassay technologies, is a valuable tool to better understand the processes associated with healing following periodontal treatment. 
INTRODUCTION:

Periodontitis is a chronic inflammatory disease that is caused by the bacterial biofilm and eventually results in destruction of the tooth’s supporting apparatus and subsequent tooth loss1. The prevalence of periodontitis, is calculated as 46% in adults, according to the 2009-2010 data from the National Health and Nutrition Examination Survey (NHANES)2. The first line of treatment of periodontal disease still remains non-surgical periodontal treatment (NSPT) that yields significant clinical improvements for probing pocket depth (PPD) and clinical attachment levels (CAL)3. Furthermore, following NSPT, the treatment response can be maintained long term, if adherence to maintenance every three months is achieved, irrespective of personal oral hygiene post-treatment4.
Gingival crevicular fluid (GCF) is both a physiologic fluid as well as an inflammatory exudate present in the gingival crevice5. Considering that periodontitis is an inflammatory disease and that the sampling of GCF is non-invasive and readily obtained chair side, it is with no surprise that it has been extensively used to profile health and disease with the prospect of serving as a diagnostic and monitoring tool6. However, since GCF also rests in close proximity with the periodontal tissues it can thus reflect the wound healing process following treatment. 
Most of the investigations of GCF markers and mediators till today have used single candidate protein immunoassays7. Given that the processes, such as inflammation, wound healing and regeneration or repair following periodontal treatment, involve a wide range of molecules exerting multiple functions, wider scale analyses are necessary to identify the molecules involved, their associations and the shifts in their expression thereby characterizing these processes. To that end, the use of multiplex immunoassays that allow the simultaneous detection of multiple analytes using samples of only a few microliters is attractive. Multiplex immunoassays can be planar assays, where the ligands are immobilized on a solid 2-D support, such as the the Q-PlexTM array (Quansys Biosciences) or bead-based suspension assays, where the ligands are immobilized with the sample in liquid phase, such as LuminexTM and Bio-PlexProTM 8. Furthermore, bead-based immunoassays can employ either magnetic or non-magnetic beads9. Bead-based immunoassays work using antibodies specific to selected analytes, either using set profiles or allowing customization, that are coated on the micro-beads. Following incubation of the samples with the beads, a detection antibody cocktail is added that binds to the conjugate of bead-analyte. The assay results are read in instruments that identify the analyte detected and quantify the signal of the analyte bound. However, a limited number of investigations have employed multiplex bead immunoassays to identify GCF markers and monitor their changing levels following periodontal treatment.   
A previous investigation from our group concluded that early time points following the intervention are critical for the detection of shifts in the GCF markers’ levels10. In addition, the wound healing inflammatory and early granulation tissue formation phase spans approximately 2 weeks following periodontal treatment11. Consequently, for this work we used the cutoff of 2 weeks following NSPT to represent the early healing phase. In addition, as 6-8 weeks following NSPT is the most commonly used follow-up time for the collection of clinical measures in periodontal literature and 3 or 6 months following NSPT comprise part of the maintenance phase, these time periods were selected to represent the average and late healing periods. 




Protocol and registration: 
The present systematic review followed the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses) guidelines12 (Supplemental Material 1) and was registered with PROSPERO under the ID number CRD42020159098.

PICO question:
The PICO question (Patient, Intervention, Comparison and Outcome) formulated was: “In patients with periodontal disease, does the expression of gingival crevicular fluid (GCF) markers detected using multiplex bead immunoassays differ at baseline compared with early (≤30 days), average (6-8 weeks) or late (≥3 months) healing after the intervention?”

Eligibility criteria:
Types of studies: 
Human, prospective clinical studies assessing the expression of GCF markers employing multiplex bead immunoassays were considered. Only human prospective studies, published in English, with minimum five patients per group were included. 

Population:
Systemically healthy individuals with chronic periodontitis (CP) with at least one tooth with probing pocket depth (PPD) ≥ 5mm and clinical attachment loss (CAL) and evidence of radiographic bone loss or aggressive periodontitis (AgP)13,14 or periodontitis Stage III or IV were included15.

Intervention and comparison:
Non-surgical periodontal treatment, without adjunct use of antibiotics (local or systemic) or host modulation treatments. No restrictions related to technique (ultrasonic or hand instruments, full mouth disinfection or in quadrants) were initially applied to avoid omitting potentially relevant data, however these details were recorded during data extraction. 

Outcome measures:
The primary outcome of this review was the change in the expression of GCF markers (total amount and/or concentration) between baseline and various time-points post intervention. Secondary outcomes considered were the association of the changes of the GCF markers after treatment with the clinical outcome, assessed using surrogate measures such as probing pocket depth (PPD) and/or clinical attachment level (CAL). 

Information sources and electronic search: 
An electronic search was conducted by two independent reviewers (VK and NC) using MEDLINE, EMBASE, Cochrane Library, LILACS and OpenGrey for publications up to 20th January 2020. Combinations of controlled terms (MeSH and EMTREE) and keywords were utilised:

("multiplex bead immunoassay" OR "multiplex" OR "multiplex bead assay" OR "luminex" OR "multiplexed bead immunoassay" OR "multiplexed bead assay" OR "magnetic immunoassay" OR "magnetic bead immunoassay”) AND ("periodontal disease" OR "periodontitis" OR "aggressive periodontitis")

Additionally, a manual search of periodontology-related journals including: Journal of Dental Research, Journal of Clinical Periodontology, Journal of Periodontal Research and the Journal of Periodontology was performed from 2010 to 2020. The list of references of the publications included in this review, as well as the list of references in relevant GCF reviews were also screened for potential additional publications fulfilling the inclusion criteria. 

Study selection:
The search results were initially screened for relevancy by means of title, keywords and abstract, independently and in duplicate by two reviewers (VK, NC). Any conflict was resolved with discussion. At the second round of screening, the full texts of the publications remaining after the first round were assessed for inclusion in this review against the inclusion criteria described previously. The level of agreement between the two reviewers was calculated using Kappa statistics.

Data collection: 
The characteristics of the included publications were extracted by two reviewers (VK and NC). Among the characteristics extracted were: study characteristics (authors, journal of publication, year, country), the number of patients and their characteristics (age, gender, smoking status), the diagnosis and the characteristics, the details of non-surgical treatment and oral hygiene regimen, the post-operative care protocol, the follow-up period, the levels of expression of GCF markers (total amount and/or concentration), the clinical outcomes (PPD, CAL) mean and at the sampled site(s) if available, the details of the methodology employed for the GCF sampling, storage, processing and detection of the markers, the information regarding the main study outcome and power calculation of the study. If data from the included studies was missing, the authors of the publication were contacted through email, twice, and a period of 4 weeks was allowed for a response. 

Risk of bias assessment: 





The flowchart of the study selection and inclusion process is depicted in Figure 1. The initial search yielded 214 MEDLINE, 315 EMBASE, 35 Cochrane database, 28 LILACS and 1 OpenGray titles with a total of 360 after the removal of duplicates. Six additional titles were identified through hand search for a total of 366 titles. Following the first round of screening, 37 titles were considered using full-text and a total of 12 met the inclusion criteria. The kappa score for inter-reviewer agreement was 0.97 at the first round and 0.95 at the second round. A list of the studies excluded, along with the reason for exclusion can be found in Supplemental Material 2.

Study characteristics:
The characteristics of the studies included in the present review are outlined in Table 1 and Table 2. The selected studies’ samples ranged from 619 to 3220, while one study21 did not specify the number of subjects included, but rather reported the number of sites analyzed, a total of 52. All studies included systemically healthy individuals, however variation in the smoking status was observed. Non-smokers were included in 5 studies22, 23, 24, 25, 26, while smokers were included in 6 studies19, 21, 27, 28, 29, 30 and one study did not report the smoking status of the individuals included20. 
Of the included studies, seven were RCTs20, 23, 24, 26, 28, 29, 30, one was a multi-center prospective intervention study25 and four studies did not report their design19, 21, 22, 27. In addition, five of the included RCTs were split-mouth studies20, 24, 26, 28, 30. 
Six of the included studies included patients with chronic periodontitis19, 21, 24, 25, 29, 30, three studies included patients with aggressive periodontitis22, 23, 26, one study included both patients with chronic and aggressive periodontitis27 and two studies did not specify the diagnosis of the patients included20, 28. 
The treatment of the studies‘ participants included scaling and root planing (SRP) over one session24, 25, two sessions19, four sessions22, maximum of six session23, 29, or spanning over 48 hours26 with some not reporting any details20, 21, 27, 28, 30. For SRP, hand instruments were used in three studies20, 23, 27, a combination of hand instruments and ultrasonic in six studies22, 24, 25, 26, 28, 30 and three studies did not provide details of the instruments used19, 21, 29. 
Most of the included studies were powered for clinical measures20, 24, 26, 29, 30, while five of the included studies did not report the primary outcome nor any power calculation19, 21, 23, 27, 28. One study was powered for the serum levels of c-reactive protein as the primary outcome25, whereas only one study was powered for the GCF marker, vascular endothelial growth factor (VEGF), as the primary outcome22. 
For the GCF sampling methodology, most of the studies used paper strips19, 22, 23, 24, 25, 26, 27, 28, 29, 30 (Periopaper), one study used paper points21 and one study used membrane strips20. Eight of the included studies reported the duration of sampling as 30 seconds19, 21, 22, 23, 25, 27, 28, 29, one study as 20 seconds20 and three studies as 15 seconds24, 26, 30. In regard to the storage of GCF samples, most of the included studies reported storing the GCF samples at -80° C19, 22, 23, 25, 27, 6 studies at -20° C20, 21, 24, 26, 28, 30 and one study at -40° C29. The eluting buffer most commonly used was phosphate buffered saline21, 22, 24, 25, 26, 27, 28, 29, 30 (PBS), while sodium phosphate buffer19 and assay buffer20, 23 were also used. In addition, three studies reported using adjunct Tween-20 during elution of the samples24, 26, 30, one study reported adjunct use of bovine serum albumin25 (BSA) and one of protease inhibitors19. 
When considering the unit for reporting GCF expression levels, most studies used pg/30sec19, 21, 27, 28, 29, one study used the unit of pg/20sec20, four studies reported concentrations23, 24, 25, 26 (pg/μL), one study reported both amounts and concentrations22 and one study reported results in pg/mg, normalizing the result to the total protein detected30. 
Finally, expression levels regarding the following 31 GCF markers were extracted from the included studies: IL-1β: interleukin 1-beta, IL-1α: interleukin 1-alpha, IL-1ra: interleukin 1 receptor antagonist, IL-2: interleukin 2, IL-3: interleukin 3, IL-4: interleukin 4, IL-5: interleukin 5, IL-6: interleukin 6, IL-7: interleukin 7, IL-8: interleukin 8, IL-9: interleukin 9, IL-10: interleukin 10, IL-12: interleukin 12, IL-12(p40): interleukin 12-p40, IL-12(p70): interleukin 12-p70, IL-13: interleukin 13, IL-17: interleukin 17, TNF-α: tumor necrosis factor alpha, IFN-γ: interferon gamma, MMP-8: matrix metalloproteinase 8, PDGF-bb: platelet derived growth factor bb, VEGF: vascular endothelial growth factor, b-FGF (FGF-2): basic fibroblast growth factor, GM-CSF: granulocyte-macrophage colony-stimulating factor, G-CSF: granulocyte colony-stimulating factor, MCP-1: monocyte chemoattractant protein-1, MIP-1a: macrophage inflammatory protein 1-alpha or chemokine ligand 3 (CCL3), MIP-1b: macrophage inflammatory protein 1-beta or chemokine ligand 4 (CCL4), IP-10: interferon gamma-induced protein 10 or chemokine 10 (CXCL10), RANTES: chemokine ligand 5 or CCL5 and Eotaxin. 

Synthesis of results: 
Clinical and GCF data from the included studies are presented in detail in Tables 1, 2 and 3. GCF numerical data per marker were not available in the published manuscripts for four studies22, 26, 29, 30. Following contact with the authors, numerical GCF data were provided only by Romano et al.22 and Soares et al.30 and the data were included in Table 3. The results of Emingil et al.29 and Moreira et al.26 were qualitatively interpreted and incorporated in Table 3. Due to the significant heterogeneity of the included studies, in regard to the methodology employed, a meta-analysis was not performed. 

Early healing time (≤30 days): 
In regard to early healing after NSPT, only a limited number of studies were available. Specifically, Giannopoulou et al.20, Soares et al.30 and Moreira et al.26 reported on the GCF marker levels at 2 weeks, Qadri et al.28 at 1 week and Morozumi et al.25 at 1 day post-intervention. 
For IL-1β, data was available from four studies20, 26, 28, 30. All four studies agreed that an increase in the total amount of IL-1β at these early time points was observed. Furthermore, Soares et al.30 observed a more highlighted increase of IL-1β levels at deep sites (PD ≥ 7 mm) compared with moderately deep sites (PD= 5-6 mm). 
Similarly, for IL-10 a significant increase in this marker’s levels was observed in two studies26, 30, that was even more highlighted for the initially deep pockets26, 30. 
For the remaining markers, conflicting results were observed. In particular, for IL-4, one study25 reported non-detectable levels at 1-day post-treatment and one study28 reported a decrease at 1-week post-treatment. For IL-6, one study25 reported a significant increase at 1-day post-treatment, while another study28 reported a minor decrease 1-week post-treatment. For IFN-γ, a small increase in concentration was noted for 1-day post operatively in one study25, while another study20 reported similar levels at 2-weeks post-intervention. Finally, one study20 reported an increase for VEGF and a decrease for b-FGF at 2-weeks post-treatment. 
Interestingly, for TNF-α, three studies25, 26, 30 reported an increase in the levels of the marker at 1-day post treatment and 2-weeks post treatment, whereas one study20 noted similar levels of the marker at 2 weeks following treatment. Notably, Soares et al.30 reported a marked increase in TNF-α levels in deep pockets (PD ≥ 7 mm), as compared with moderately deep pockets (PD= 5-6 mm). 


Average healing time (6-8 weeks):
For the average healing period following NSPT, four studies were available19, 20, 21, 25. All four studies reported GCF markers levels 6 to 8 weeks following treatment. 
For IL-1β, data were available from 3 studies19, 20, 21. Two of these studies agreed that a decrease in the levels of IL-1β was observed19, 21 during this period, while one study20 observed similar IL-1β levels 6-8 weeks after treatment as those recorded at baseline. However, the study by Giannnopoulou et al.20 included individuals receiving selective SRP while on supportive periodontal therapy, 3 to 24 months following a round of active treatment, and may thus represent a cohort of patients with limited inflammation present at the time of baseline sample collection. 
Furthermore, agreement was observed for IL-1α and IL-6 expression levels. In particular, for IL-1α, two studies19, 21 and for IL-6 three studies19, 21, 25 all agreed that the markers’ levels decreased significantly 6 to 8 weeks following periodontal treatment. 
Furthermore, all four studies19, 20, 21, 25 reported on TNF-α levels 6-8 weeks following the intervention. One study19 reported undetectable levels for the marker both at baseline and at 6-8 weeks post-treatment. Two studies20, 21 showed a decrease in the TNF-α levels, while one study25 reported a slight increase. It is worth noting that while Giannopoulou et al.20 and Reis et al.21 collected GCF samples at the 8-week time-point, Morozumi et al.25 collected GCF samples at 6-weeks following NSPT. Therefore, this difference in sampling timings may be associated with the different trends observed in the GCF markers’ levels. 
For IFN-γ levels, three studies were available19, 20, 25. Similar to TNF-α, a decrease in IFN-γ levels was noted in two investigations19, 20, whereas similar levels were reported in the study by Morozumi et al25. As mentioned previously, this disparity between studies may be justified by the differences in the sampling time. 
Finally, for all GM-CSF, MCP-1 and MIP-1a markers two studies19, 20 both observed a decrease in these markers’ levels at 6-8 weeks following NSPT. 


Late healing time (≥12 weeks):
Regarding the late healing following NSPT, nine studies reported on the GCF markers levels20, 22, 23, 24,  26, 27, 28, 29, 30.  Four studies reported data at 3 months26, 27, 28, 30, three studies reported GCF data both at 3 and 6 months20, 23, 29 and two additional studies reported GCF data only at 6 months following NSPT22, 24. 
For IL-1β, there was agreement among studies22, 24, 26, 27, 28, 30 of a significant decrease in IL-1β levels 3 months following NSPT. However, no such agreement was reached for the marker levels at 6 months. While Romano et al.22 and Oliveira et al.23 reported a significant decrease in IL-1β levels that was maintained at 6 months post treatment, two studies20, 24 reported values that were higher than those initially noted before treatment20 or higher than the respective values at 3 months24. Interestingly, in the investigation by Giannopoulou et al.20 the authors also reported that half of the treated sites presented with bleeding upon probing at the 6-month time-point. On the contrary, in the investigation by Kolbe et al.24 stable bleeding upon probing scores were reported from 3 to 6 months, therefore the differences in the trends of IL-1β at 6 months may not be associated with the bleeding indexes.  Although not necessarily critical, it is however worth noting that the GCF samples in the studies by Romano et al.22 and Oliveira et al.23 were stored at -80° C, whereas the samples in the studies by Giannopoulou et al.20 and Kolbe et al.24 were stored at -20° C, for unspecified periods of time.
For IL-4, there was agreement across four studies24, 27, 28, 29 for a decrease in the marker’s levels 3 months following treatment. For the 6-month time-point, Kolbe et al.24 reported a significant increase from 3 to 6 months post treatment, whereas Emingil et al.29 noted a further decrease in IL-4 levels. 
Similarly, for IL-6, a decrease in levels 3 months following treatment was noted in two studies24, 28. Whereas that decrease was maintained at 6 months following treatment in the study by Kolbe et al.24, another study23, involving generalized aggressive periodontitis subjects, reported a significant increase in IL-6 levels, compared with the respective pre-treatment levels, despite maintenance of the clinical improvements reported at 3 months. 
For IL-10, a slight decrease in levels was noted in three studies24, 26, 30, with the exception of sites with initially increased PD (≥7mm)30 and one study29 that reported levels similar to those recorded at baseline. Furthermore, the decrease in IL-10 levels was followed by an increase to baseline levels by 6 months23, 24. 
When considering regenerative GCF markers, for example TNF-α, a significant decrease was noted 3 months following NSPT in three studies22, 24, 30, while one study26 reported similar TNF-α levels as those noted at baseline. Notably, both in the study by Soares et al.30 and the study by Moreira et al.26 the levels of TNF-α for moderate pockets of 5-6mm were increased at 3 months following treatment. Furthermore, the decreased TNF-α levels noted in most investigations 3 months after treatment were maintained until the 6-month time point, as per two studies22, 24.  On the contrary, two different studies20, 23 reported at 6 months higher TNF-α levels, compared to those recorded at baseline. As previously noted, in the investigation by Giannopoulou et al.20 half of the treated sites presented with bleeding upon probing at the 6-month time-point, whereas the investigation by Oliveira et al.23 included generalized aggressive periodontitis subjects. 
For IFN-γ levels, two studies reported a significant decrease in the marker’s levels 3 months following treatment24, 27. Furthermore, Giannopoulou et al.20 and Oliveira et al.23 reported reduced IFN-γ levels 6 months following treatment and this was further reinforced by the investigation by Kolbe et al.24 noting even further reduction of IFN-γ levels from 3 to 6 months post-treatment. Therefore, the improvement of clinical indices following NSPT was accompanied by a reduction of the IFN-γ levels.
Finally, considering VEGF levels, one study22 reported a significant reduction in the marker’s levels 3 months following treatment that was maintained until the 6-month time-point. However, Giannopoulou et al.20 noted an increase in VEGF levels 6 months following NSPT, possibly associated with the increased occurrence of bleeding upon probing at this time-point. 

Risk of bias assessment: 




This systematic review investigated the levels of 31 GCF markers, broadly associated with inflammation and regeneration, at an early, an average and a late time point after NSPT. Despite the methodological differences across investigations, that did not allow for a meta-analysis to be conducted, several conclusions were drawn. 
At the early healing period (≤ 30 days) following NSPT, an increase for IL-1β was noted, accompanied by a trend for an even more marked increase at the initially deeper sites. At this early time-point after treatment, TNFα and IL-10 were also reported to be increased. At the average healing period (6-8 weeks) following treatment, several markers were found in reduced levels, compared to their respective baseline values. In particular, IL-1β, IL-1α, IL-6, TNF-α, IFN-γ, GM-CSF, MCP-1, MIP-1α were all reduced, compared to pre-treatment levels. At the late healing period (3 months) after NSPT, several markers and specifically, IL-1β, IL-4, IL-6, IL-10, TNF-α and IFN-γ were found at reduced levels. However, at 6 months following treatment some investigations reported a subsequent increase for IL-1β, IL-4, IL-6, IL-10, TNF-α and VEGF. Although the data was limited and does not allow us to draw robust conclusions, these findings may relate to the increased levels of inflammation at the 6-month time point accompanied by high prevalence of Silness & Loe plaque indices more than 020, 31, the limited information or lack of supportive periodontal treatment23 and the inclusion of individuals with generalised aggressive periodontitis23. 
A systematic review and meta-analysis of GCF markers’ levels previously concluded7 that firstly, significantly higher levels of IL-1β, IFN-γ, IL-6 and MCP-1 were observed in periodontally diseased sites, compared with healthy controls and secondly, IL-1β and IL-17 levels were significantly reduced, whereas IL-4 levels significantly increased following NSPT. Furthermore, some evidence suggested that MCP-1 also decreased following treatment7. With most of the studies included in the Stadler et al. systematic review7 reporting on follow-up periods reflecting the average and late healing time-points, as defined in the present review, our results agree in regard to the levels of IL-1β and MCP-1 following NSPT. 
The present review is the first to examine the levels of GCF markers of inflammation and regeneration at early time points following NSPT. As previously reported by our group10, the expression of GCF markers at early time points following periodontal treatment is critical as it may define whether the healing process progresses towards regeneration or repair. Consequently, the investigation of regeneration or inflammation GCF markers early post-intervention provides insight into the wound healing processes and in the future, it may aid in the prediction of the periodontal treatment response. 
Tumor necrosis factor α (TNF-α) is a cytokine associated with bone resorption and its presence has been well documented in patients with periodontal disease32. Similarly, IL-1β is a pro-inflammatory cytokine produced mainly by macrophages and monocytes, established for its marked presence in inflammatory periodontal tissues and GCF33. The finding of the present review of an upregulation of inflammatory markers, such as IL-1β and TNF-α, at early time-points (up to 2 weeks) following periodontal treatment and a subsequent reduction at later time-points further supports the theory of coupling of the processes of inflammation and regeneration. Garlet & Giannobile34 have previously described the concept of “constructive inflammation”, where the resolution of destructive inflammation is interconnected with anabolic functions via elements, such as IL-4 for example, mediating this transition. Along the same lines, these findings of an upregulation of inflammatory markers early following NSPT agree with previous observations of activation of an acute phase inflammatory response in serum35.
Another important point to highlight is the differentiated response of GCF markers that is observed in smokers who present a delay in wound healing through multiple detrimental effects in all phases of the wound-healing process, such as hemostasis, inflammation, proliferation and remodeling36, 37. In a single-arm clinical trial by Bunaes et al.38 25 smokers and 25 non-smokers with periodontal disease were followed up after surgical and non-surgical periodontal treatment. Despite the fact that for the non-smokers, the trends for all markers as described in this present review were followed, a differentiated response was observed for the group of smokers. Particularly, whereas a decrease of IL-6 was noted for the non-smokers, smokers presented a marked increase of the marker 3 months following the intervention38. Similarly, no reduction in TNF-α levels for smokers was observed following treatment, as reported for the non-smoking group38. These findings are in agreement with literature suggesting the existence of a differentiated response in smokers. While limited data is available on the GCF levels of smokers following periodontal treatment, higher levels of TNF-α have been observed in GCF of smokers with chronic periodontitis, compared with non-smokers with chronic periodontitis39, 40. Therefore, the variability in the smoking status across the included investigations of this review may explain the contradictory results observed for some GCF inflammatory markers. 
Interestingly, a recent systematic review and meta-analysis observed similar clinical improvements following NSPT with different methodologies41. The clinical outcomes following NSPT with sonic/ultrasonic versus hand instruments were similar, as were the clinical outcomes following quadrant-wise versus full-mouth NSPT41. In the present review, variations were observed between studies for the methodology employed for NSPT, however as these variations do not affect the clinical outcomes, we would expect they would not affect the levels of expression of GCF markers. 
Finally, along with the possible lack of statistical power for GCF levels in all but one of the investigations included, a large variation was observed in the methodology employed for GCF sampling, storage and analysis across investigations10, 42, 43. This methodology variation introduces confounders in the interpretation of the data presented in this review. For example, the materials used for the GCF sampling (PerioPaper, paper point, membrane strip), the use of single or pooled samples, the duration of GCF collection (30seconds, 20 seconds, 15 seconds), the depth of the insertion of the strip (entrance or until resistance was felt), the storage (-80oC or -40oC or -20oC), the elution methods and eluting buffers or the commercial assay used for the analysis, and the time between collection and analysis introduce variations that may affect the conclusions drawn and their generalizability. 
Aiming in reducing the GCF methodology variability, multiplex immunoassays not only allow the detection of multiple analytes at the same time, but most importantly for periodontal research, require minimum volume of samples. Previously employed techniques, such as ELISA, required the same loading sample as multiplex immunoassays but produced results for only one selected marker. Considering the limited availability of GCF, especially at non-diseased or successfully treated sites, the multiplex immunoassay emerges as a promising tool for simultaneously measuring multiple markers in a single GCF sample.  
The synthesis of the data as presented in this review provides a first approach towards a better understanding of the trends of change of GCF markers associated with inflammation and regeneration, at different time-points following the non-surgical periodontal treatment using the same method of analysis, namely multiplex bead immunoassays.
A limitation of the included studies identified in the present review was the lack of uniformity in reporting clinical parameters, for example site specific compared with full mouth probing depths and attachment levels, bleeding on probing or plaque scores. This lack of information did not allow for a correlation of the GCF marker trends observed with the clinical outcomes following non-surgical periodontal treatment. 
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Figure 1. PRISMA flow diagram.






Table 1. Clinical material and methods of the studies included 

Table 2. GCF materials and methods of the included studies

Table 3. GCF levels at baseline and early, average, late healing. 
 
Table 4. Risk of bias assessment of non-comparative observational studies using the MINORS tool. Studies were assessed in 8 items and could receive 0-2 points for each item for a total score ranging from 0 to 16 points. 
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